Yüklüyor......
Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer
Oncogenic BRAF(V600E) mutations activate MAP kinase signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer (CRC). In BRAF(V600E) mutant CRCs, treatment failure may be related to BRAF(V600E) -mediated apoptosis resistance that occurs by an as yet...
Kaydedildi:
| Yayımlandı: | Mol Cancer Ther |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5136313/ https://ncbi.nlm.nih.gov/pubmed/27765849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0017 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|